Antianginal and anti-ischemic efficacy of nisoldipine in stable angina pectoris: A randomized, double-blind placebo-controlled trial

Ying Hwa Chen, Ru Chi Liu, Shih Pu Wang

研究成果: 雜誌貢獻 › 文章

摘要

Background. Nisoldipine, a dihydropyridine calcium antagonist, is a potent vasodilator with selectivity for the coronary tree. The purpose of the study was to evaluate the onset and duration of antianginal and anti-ischemic efficacy of a single oral dose of nisoldipine compared with placebo in patients with stable angina pectoris. Methods. In 33 patients with stable angina pectoris, nisoldipine was tested (10 mg daily) in a randomized, double-blind, placebo-controlled study. Drugs having antianginal and anti-ischemic effects (except sublingual nitroglycerin) were withdrawn. Patients underwent a four-day 'washout' phase, then were randomly assigned to nisoldipine (10 mg daily) or placebo for six days. On Day 4 and Day 10, three times of treadmill exercise testing were performed before daily medication was given, 2 hours and 6 hours after dosing, respectively. Results. Twenty-eight patients (14 taking nisoldipine and 14 taking placebos) completed the study and were included in the statistical evaluation. Compared with placebo, total exercise duration increased significantly during all three sequential exercise testing in patients receiving nisoldipine. The frequency of anginal attacks decreased significantly while patients were receiving nisoldipine (0.29 ± 0.44/patient/day versus 0.14 ± 0.26/patient/day, p <0.05). Similarly, there was a trend toward a decrease in the consumption of sublingual nitroglycerin while patients were receiving nisoldipine. Adverse effects were mild. Conclusions. The study confirms that nisoldipine is an active antianginal and anti-ischemic agent, with an acceptable side effect profile when used as monotherapy. The anti-ischemic effect lasted more than six hours and the drug could be administered once daily.
原文英語
頁（從 - 到）323-328
頁數6
期刊Chinese Medical Journal (Taipei)
卷58
發行號5
出版狀態已發佈 - 十一月 1996
對外發佈Yes

指紋

Nisoldipine
Stable Angina
Placebos
Nitroglycerin
Exercise
Vasodilator Agents
Pharmaceutical Preparations
Calcium

ASJC Scopus subject areas

  • Medicine(all)

引用此文

Antianginal and anti-ischemic efficacy of nisoldipine in stable angina pectoris : A randomized, double-blind placebo-controlled trial. / Chen, Ying Hwa; Liu, Ru Chi; Wang, Shih Pu.

於: Chinese Medical Journal (Taipei), 卷 58, 編號 5, 11.1996, p. 323-328.

研究成果: 雜誌貢獻 › 文章

Chen, YH, Liu, RC & Wang, SP 1996, 'Antianginal and anti-ischemic efficacy of nisoldipine in stable angina pectoris: A randomized, double-blind placebo-controlled trial', Chinese Medical Journal (Taipei), 卷 58, 編號 5, 頁 323-328.
Chen YH, Liu RC, Wang SP. Antianginal and anti-ischemic efficacy of nisoldipine in stable angina pectoris: A randomized, double-blind placebo-controlled trial. Chinese Medical Journal (Taipei). 1996 11月;58(5):323-328.
Chen, Ying Hwa ; Liu, Ru Chi ; Wang, Shih Pu. / Antianginal and anti-ischemic efficacy of nisoldipine in stable angina pectoris : A randomized, double-blind placebo-controlled trial. 於: Chinese Medical Journal (Taipei). 1996 ; 卷 58, 編號 5. 頁 323-328.
@article{c59e850a2bb044eeaaa77ea9e9ced254,
title = "Antianginal and anti-ischemic efficacy of nisoldipine in stable angina pectoris: A randomized, double-blind placebo-controlled trial",
abstract = "Background. Nisoldipine, a dihydropyridine calcium antagonist, is a potent vasodilator with selectivity for the coronary tree. The purpose of the study was to evaluate the onset and duration of antianginal and anti-ischemic efficacy of a single oral dose of nisoldipine compared with placebo in patients with stable angina pectoris. Methods. In 33 patients with stable angina pectoris, nisoldipine was tested (10 mg daily) in a randomized, double-blind, placebo-controlled study. Drugs having antianginal and anti-ischemic effects (except sublingual nitroglycerin) were withdrawn. Patients underwent a four-day 'washout' phase, then were randomly assigned to nisoldipine (10 mg daily) or placebo for six days. On Day 4 and Day 10, three times of treadmill exercise testing were performed before daily medication was given, 2 hours and 6 hours after dosing, respectively. Results. Twenty-eight patients (14 taking nisoldipine and 14 taking placebos) completed the study and were included in the statistical evaluation. Compared with placebo, total exercise duration increased significantly during all three sequential exercise testing in patients receiving nisoldipine. The frequency of anginal attacks decreased significantly while patients were receiving nisoldipine (0.29 ± 0.44/patient/day versus 0.14 ± 0.26/patient/day, p <0.05). Similarly, there was a trend toward a decrease in the consumption of sublingual nitroglycerin while patients were receiving nisoldipine. Adverse effects were mild. Conclusions. The study confirms that nisoldipine is an active antianginal and anti-ischemic agent, with an acceptable side effect profile when used as monotherapy. The anti-ischemic effect lasted more than six hours and the drug could be administered once daily.",
keywords = "calcium channel blocker, nisoldipine, stable angina pectoris",
author = "Chen, {Ying Hwa} and Liu, {Ru Chi} and Wang, {Shih Pu}",
year = "1996",
month = "11",
language = "English",
volume = "58",
pages = "323--328",
journal = "Journal of the Chinese Medical Association",
issn = "1726-4901",
publisher = "Elsevier Taiwan LLC",
number = "5",

}

TY - JOUR

T1 - Antianginal and anti-ischemic efficacy of nisoldipine in stable angina pectoris

T2 - A randomized, double-blind placebo-controlled trial

AU - Chen, Ying Hwa

AU - Liu, Ru Chi

AU - Wang, Shih Pu

PY - 1996/11

Y1 - 1996/11

N2 - Background. Nisoldipine, a dihydropyridine calcium antagonist, is a potent vasodilator with selectivity for the coronary tree. The purpose of the study was to evaluate the onset and duration of antianginal and anti-ischemic efficacy of a single oral dose of nisoldipine compared with placebo in patients with stable angina pectoris. Methods. In 33 patients with stable angina pectoris, nisoldipine was tested (10 mg daily) in a randomized, double-blind, placebo-controlled study. Drugs having antianginal and anti-ischemic effects (except sublingual nitroglycerin) were withdrawn. Patients underwent a four-day 'washout' phase, then were randomly assigned to nisoldipine (10 mg daily) or placebo for six days. On Day 4 and Day 10, three times of treadmill exercise testing were performed before daily medication was given, 2 hours and 6 hours after dosing, respectively. Results. Twenty-eight patients (14 taking nisoldipine and 14 taking placebos) completed the study and were included in the statistical evaluation. Compared with placebo, total exercise duration increased significantly during all three sequential exercise testing in patients receiving nisoldipine. The frequency of anginal attacks decreased significantly while patients were receiving nisoldipine (0.29 ± 0.44/patient/day versus 0.14 ± 0.26/patient/day, p <0.05). Similarly, there was a trend toward a decrease in the consumption of sublingual nitroglycerin while patients were receiving nisoldipine. Adverse effects were mild. Conclusions. The study confirms that nisoldipine is an active antianginal and anti-ischemic agent, with an acceptable side effect profile when used as monotherapy. The anti-ischemic effect lasted more than six hours and the drug could be administered once daily.

AB - Background. Nisoldipine, a dihydropyridine calcium antagonist, is a potent vasodilator with selectivity for the coronary tree. The purpose of the study was to evaluate the onset and duration of antianginal and anti-ischemic efficacy of a single oral dose of nisoldipine compared with placebo in patients with stable angina pectoris. Methods. In 33 patients with stable angina pectoris, nisoldipine was tested (10 mg daily) in a randomized, double-blind, placebo-controlled study. Drugs having antianginal and anti-ischemic effects (except sublingual nitroglycerin) were withdrawn. Patients underwent a four-day 'washout' phase, then were randomly assigned to nisoldipine (10 mg daily) or placebo for six days. On Day 4 and Day 10, three times of treadmill exercise testing were performed before daily medication was given, 2 hours and 6 hours after dosing, respectively. Results. Twenty-eight patients (14 taking nisoldipine and 14 taking placebos) completed the study and were included in the statistical evaluation. Compared with placebo, total exercise duration increased significantly during all three sequential exercise testing in patients receiving nisoldipine. The frequency of anginal attacks decreased significantly while patients were receiving nisoldipine (0.29 ± 0.44/patient/day versus 0.14 ± 0.26/patient/day, p <0.05). Similarly, there was a trend toward a decrease in the consumption of sublingual nitroglycerin while patients were receiving nisoldipine. Adverse effects were mild. Conclusions. The study confirms that nisoldipine is an active antianginal and anti-ischemic agent, with an acceptable side effect profile when used as monotherapy. The anti-ischemic effect lasted more than six hours and the drug could be administered once daily.

KW - calcium channel blocker

KW - nisoldipine

KW - stable angina pectoris

UR - http://www.scopus.com/inward/record.url?scp=0030459963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030459963&partnerID=8YFLogxK

M3 - Article

C2 - 9037847

AN - SCOPUS:0030459963

VL - 58

SP - 323

EP - 328

JO - Journal of the Chinese Medical Association

JF - Journal of the Chinese Medical Association

SN - 1726-4901

IS - 5

ER -

存取文件